Related references
Note: Only part of the references are listed.Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero
Emma Flanagan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)
Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis
Nicholas E. Burr et al.
GUT (2022)
Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy
Fernando Bermejo et al.
INFLAMMATORY BOWEL DISEASES (2022)
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis
Juan S. Lasa et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)
Outcomes of Standard and Intensified Dosing of Ustekinumab for Chronic Pouch Disorders
Rahul S. Dalal et al.
INFLAMMATORY BOWEL DISEASES (2022)
Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease
Jacob E. Ollech et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Intravenous Ustekinumab Reinduction Is Effective in Prior Biologic Failure Crohn's Disease Patients Already on Every-4-Week Dosing
Rocio Sedano et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab
Anne Hu et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Dual Targeted Therapy: A Possible Option for the Management of Refractory Inflammatory Bowel Disease
Giuseppe Privitera et al.
JOURNAL OF CROHNS & COLITIS (2021)
Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis
Akshita Gupta et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies
William J. Sandborn et al.
INFLAMMATORY BOWEL DISEASES (2021)
Effectiveness and Safety of Ustekinumab Intensification at 90 mg Every 4 Weeks in Crohn's Disease: A Multicentre Study
Mathurin Fumery et al.
JOURNAL OF CROHNS & COLITIS (2021)
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
Dan Turner et al.
GASTROENTEROLOGY (2021)
Orphan patients with inflammatory bowel disease-when we treat beyond evidence
Giuseppe Privitera et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2021)
Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases
Giuseppe Privitera et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Real-World Comparison of Tofacitinib vs Ustekinumab Among Bio-Exposed Patients With Ulcerative Colitis: A Propensity Score Analysis
Rahul S. Dalal et al.
INFLAMMATORY BOWEL DISEASES (2021)
Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry
Maria Chaparro et al.
JOURNAL OF CROHNS & COLITIS (2021)
Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study
Mathurin Fumery et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)
Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy
Giuseppe Privitera et al.
AUTOIMMUNITY REVIEWS (2021)
One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy
Michele Francesco Chiappetta et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2021)
Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs
Georg Schett et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Combining Cyclosporine With Ustekinumab in Acute Severe Ulcerative Colitis
Seth R. Shaffer et al.
ACG CASE REPORTS JOURNAL (2021)
Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study
Katarina Mitrova et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2021)
One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study
Jasbir Dhaliwal et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)
Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
Siddharth Singh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
IL-12 and Mucosal CD14+ Monocyte-Like Cells Induce IL-8 in Colonic Memory CD4+ T Cells of Patients With Ulcerative Colitis but not Crohn's Disease
Laurence Chapuy et al.
JOURNAL OF CROHNS & COLITIS (2020)
Efficacies and Related Issues of Ustekinumab in Japanese Patients with Crohn's Disease: A Preliminary Study
Takako Miyazaki et al.
DIGESTION (2020)
Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis
Omoniyi J. Adedokun et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis
Siddharth Singh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis
Margaux Welty et al.
CURRENT MEDICAL RESEARCH AND OPINION (2020)
Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study
Aurelien Amiot et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis
Thomas Ochsenkuehn et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2020)
Difference in treatment outcomes between clinical trials and real-life clinical practice: ustekinumab in ulcerative colitis
Daniela Pugliese et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2020)
Paradoxical gastrointestinal effects of interleukin-17 blockers
Marine Fauny et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Effectiveness and safety of ustekinumab in patients with hidradenitis suppurativa using intravenous induction
Eva M. Sanchez-Martinez et al.
DERMATOLOGIC THERAPY (2020)
Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review
Javier P. Gisbert et al.
DRUGS (2020)
S0716 Real World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From Two Tertiary IBD Centers in the U.S.
Simon Hong et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
Relationship Between Combined Histologic and Endoscopic Endpoints and Eff i cacy of Ustekinumab Treatment in Patients With Ulcerative Colitis
Katherine Li et al.
GASTROENTEROLOGY (2020)
Successful cyclosporin and ustekinumab combination therapy in a patient with severe steroid-refractory ulcerative colitis
Ingo Ganzleben et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2020)
Expansion of IL-23 receptor bearing TNFR2+T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease
Heike Schmitt et al.
GUT (2019)
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects
Andreas Sturm et al.
JOURNAL OF CROHNS & COLITIS (2019)
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study
Daniela Pugliese et al.
DIGESTIVE AND LIVER DISEASE (2019)
Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease
Matthias Friedrich et al.
IMMUNITY (2019)
Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis
Jacob E. Ollech et al.
DIGESTIVE DISEASES AND SCIENCES (2019)
Inflammatory cytokines: from discoveries to therapies in IBD
Irene Marafini et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
B. E. Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis
Atul Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort
Kimberly N. Weaver et al.
INFLAMMATORY BOWEL DISEASES (2019)
IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting
Alexander R. Moschen et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Anti-IL-23 receptor monoclonal antibody prevents CD4+ T cell-mediated colitis in association with decreased systemic Th1 and Th17 responses
Emiko Imamura et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Systematic Review With Meta-Analysis: Anti-TNF Therapy in Refractory Pouchitis and Crohn's Disease-Like Complications of the Pouch After Ileal Pouch-Anal Anastomosis Following Colectomy for Ulcerative Colitis
Mathilde Huguet et al.
INFLAMMATORY BOWEL DISEASES (2018)
The dichotomous nature of T helper 17 cells
Brigitta Stockinger et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis
Shailja C. Shah et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study
D. Pugliese et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability
Jacob S. Lee et al.
IMMUNITY (2015)
TH17 cells transdifferentiate into regulatory T cells during resolution of inflammation
Nicola Gagliani et al.
NATURE (2015)
Optimizing anti-TNF treatments in inflammatory bowel disease
Shomron Ben-Horin et al.
AUTOIMMUNITY REVIEWS (2014)
Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: preliminary results
Tamer A. Gheita et al.
CLINICAL RHEUMATOLOGY (2014)
Management of Inflammatory Bowel Disease Patients with a Cancer History
Laurent Beaugerie
CURRENT DRUG TARGETS (2014)
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year
Luisa Guidi et al.
DIGESTIVE AND LIVER DISEASE (2014)
Cytokines in inflammatory bowel disease
Markus F. Neurath
NATURE REVIEWS IMMUNOLOGY (2014)
Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study
Marte Lie Hoivik et al.
GUT (2013)
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
Iain B. McInnes et al.
LANCET (2013)
Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population
Christina Ha et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
Genetic polymorphisms of IL-23R and IL-17A and novel insights into their associations with inflammatory bowel disease
Seung Won Kim et al.
GUT (2011)
The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity
Zhanju Liu et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2011)
Discovery and mechanism of ustekinumab A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders
Jacqueline M. Benson et al.
MABS (2011)
IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease
T. Kobayashi et al.
GUT (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene
Richard H. Duerr et al.
SCIENCE (2006)
IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis
Marika C. Kullberg et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells
Ivaylo I. Ivanov et al.
CELL (2006)
Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology
Holm H. Uhlig et al.
IMMUNITY (2006)
IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6
D Yen et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Anti-interleukin-12 antibody for active Crohn's disease
PJ Mannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17
S Aggarwal et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R
C Parham et al.
JOURNAL OF IMMUNOLOGY (2002)
A novel transcription factor, T-bet, directs Th1 lineage commitment
SJ Szabo et al.
CELL (2000)
Share Paper
